

Product Name: NVP BSK 805

Catalog No.: 5818

Batch No.: 1

CAS Number: 2320258-95-3

IUPAC Name: 8-[3,5-Difluoro-4-(4-morpholinylmethyl)phenyl]-2-[1-(4-piperidinyl)-1H-pyrazol-4-yl]quinoxaline trihydrochloride

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₂₇H₂₈F₂N₆O.3HCl.3H₂O


Batch Molecular Weight: 653.99

Physical Appearance: Yellow solid

Solubility: DMSO to 50 mM
water to 100 mM

Storage: Store at +4°C

Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 98.7% purity

¹H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	49.59	5.7	12.85
Found	49.51	5.44	12.78

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com

techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com

Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors

Tel: +1 612 379 2956

Product Name: NVP BSK 805

Catalog No.: 5818

Batch No.: 1

CAS Number: 2320258-95-3

IUPAC Name: 8-[3,5-Difluoro-4-(4-morpholinylmethyl)phenyl]-2-[1-(4-piperidinyl)-1H-pyrazol-4-yl]quinoxaline trihydrochloride

Description:

NVP BSK 805 is a potent JAK2 inhibitor (IC₅₀ = 0.48 nM). Exhibits >20-fold selectivity for JAK2 over TYK2, JAK3 and JAK1 (IC₅₀ values are 10.8, 18.7 and 31.6 nM, respectively). Inhibits proliferation and induces apoptosis of JAK2^{V617F}-bearing acute myeloid leukemia cells in vitro and in vivo. Also inhibits erythropoietin-induced polycythemia. Orally bioavailable.

Physical and Chemical Properties:


Batch Molecular Formula: C₂₇H₂₈F₂N₆O.3HCl.3H₂O

Batch Molecular Weight: 653.99

Physical Appearance: Yellow solid

Minimum Purity: ≥98%

Batch Molecular Structure:



Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 50 mM
water to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Baffert et al (2010) Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. *Mol.Cancer Ther.* **9** 1945. PMID: 20587663.

Pissot-Soldermann et al (2010) Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. *Bioorg.Med.Chem.Lett.* **20** 2609. PMID: 20231096.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com

info@bio-techne.com
techsupport@bio-techne.com

North America

Tel: (800) 343 7475

China

info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa

Tel: +44 (0)1235 529449

Rest of World

www.tocris.com/distributors
Tel:+1 612 379 2956